EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases

被引：0
|
作者：
Jiang, T. [1 ]
Zhou, C. [1 ]
机构：
[1] Tongji Univ, Shanghai Pulm Hosp, Med Oncol, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 04期
关键词：
D O I：
10.1016/S1556-0864(18)30403-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
129O
引用
收藏
页码：S74 / S74
页数：1
相关论文
共 50 条
  • [41] Survival Outcome Assessed According to Tumor Burden & Progression Patterns in Patients with EGFR Mutant NSCLC Undergoing EGFR-TKIs
    Cha, Yoon Ki
    Lee, Ho Yun
    Ahn, Myung-Ju
    Choi, Yoon-La
    Lee, Ji Hyun
    Park, Keunchil
    Kim, Seon-Jeong
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S277 - S277
  • [42] Clinical predictors of 5-year survival in patients with EGFR-mutant metastatic NSCLC treated with EGFR-TKIs.
    Lin, Jessica Jiyeong
    Cardarella, Stephanie
    Lydon, Christine A.
    Dahlberg, Suzanne Eleanor
    Jackman, David Michael
    Janne, Pasi A.
    Johnson, Bruce E.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [44] Efficacy of EGFR-TKIs vs TKIs Plus Chemotherapy as First-Line Treatment in EGFR-Mutation Lung Adenocarcinoma With Liver Metastases
    Wang, H.
    Li, M.
    Xing, R.
    Wei, C.
    Ma, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1110 - S1110
  • [45] The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
    Huang, Yen-Hsiang
    Hsu, Kuo-Hsuan
    Chin, Chun-Shih
    Tseng, Jeng-Sen
    Yang, Tsung-Ying
    Chen, Kun-Chieh
    Su, Kang-Yi
    Yu, Sung-Liang
    Chen, Jeremy J. W.
    Chang, Gee-Chen
    CANCER RESEARCH AND TREATMENT, 2022, 54 (02): : 434 - 444
  • [46] Effect of EGFR-TKIs Combined with Cerebral Radiotherapy on Prognosis of Patients with EGFR-Mutant Lung Adenocarcinoma with Brain Metastasis
    Deng, G.
    Li, Z.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2022, 114 (03): : S164 - S164
  • [47] Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
    Zheng, Hong
    Liu, Quan-Xing
    Hou, Bin
    Zhou, Dong
    Li, Jing-Meng
    Lu, Xiao
    Wu, Qiu-Ping
    Dai, Ji-Gang
    ONCOTARGET, 2017, 8 (34) : 57356 - 57364
  • [48] Impact of Brain Metastases on Healthcare Utilisation and Costs in Patients with NSCLC Treated with EGFR-TKIs
    Subramaniam, D.
    Pavilack, M.
    Huo, H.
    Shenolikar, R.
    Kong, A.
    Moynihan, M.
    Marchlewicz, E.
    Larson, C.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S880 - S880
  • [49] Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung Adenocarcinoma
    Zhang, C.
    Zhang, S.
    Yao, Y.
    Gao, Y.
    Huang, J.
    Peng, K.
    Gao, Q.
    Chen, H.
    Xu, C.
    Zhang, X.
    Wu, Y.
    Yang, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S178 - S179
  • [50] First-Line Radical Local Therapy May Provide Additional Survival Gain for Patients with EGFR-Mutant Metastatic NSCLC Receiving TKIs
    Lu, X.
    Wang, J.
    Wang, C.
    Bi, N.
    Zhou, Z.
    Wang, Y.
    Wang, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S892 - S892
12345